Skip to main content

Rate of Timely Follow-up on Positive Stool-based Tests for Colorectal Cancer Detection

CBE ID
4705e
Endorsement Status
E&M Committee Rationale/Justification

When the measure returns for maintenance (3 years), the measure developer should have:

  • Conducted additional validity testing (data element in additional EHR); and
  • Continued to monitor (e.g., qualitative assessments, empirical analyses) for unintended consequences (e.g., reduced access to colonoscopies) during implementation.
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
Next Maintenance Cycle
Fall 2027
1.6 Measure Description

This electronic Clinical Quality Measure (eCQM) reports the percentage of patients aged 45 to 75 years with at least one positive stool-based colorectal cancer screening test (i.e., high-sensitivity guaiac fecal occult blood test, fecal immunochemical test, or Cologuard) during the measurement period (i.e., calendar year) who completed a colonoscopy within 180 days after their index (i.e., first) positive stool-based test result date.

Measure Specs
General Information
1.7 Measure Type
1.7 Composite Measure
No
1.3 Electronic Clinical Quality Measure (eCQM)
1.8 Level of Analysis
1.8b Other Level of Analysis
Integrated Delivery System
1.9 Care Setting
1.9b Other Care Setting
Integrated Delivery System
1.10 Measure Rationale

Colorectal cancer is the second leading cause of cancer mortality in the United States for men and women combined [1]. In 2024, around 152,810 patients will be diagnosed with colorectal cancer and 53,010 are expected to die from it. Early detection and removal of colorectal polyps and early-stage cancers prevents disease progression and improves the odds of survival [2]. Noninvasive screening tests (e.g., stool-based tests) are available to detect markers of abnormal growths. However, delays in follow-up colonoscopy reduce the benefits of screening by leading to missed opportunities for timely intervention.

Multiple guidelines recommend using stool-based tests (i.e., high-sensitivity gFOBT, FIT, FIT-DNA) as noninvasive screening options, and colonoscopy as the gold standard for follow-up in patients with a positive stool-based test result [3, 4, 5]. The American Gastroenterological Association (AGA) recommends that at least 95% of patients receive a colonoscopy within 6 months of a positive noninvasive test result to complete the full screening process [6]. Existing literature supports this timeframe as patients who received their colonoscopies after the 6-month mark had a significantly higher risk of being diagnosed with more advanced stages of cancer [7]. 

Rates of timely follow-up in the U.S. are far below the benchmark established by the AGA. A 2023 study examining 39 U.S. health care organizations reported follow-up colonoscopy rates around 50% within 180 days of a positive stool-based test [8]. A follow-up study in 2024 reported rates of around 56.1% within the same timeframe [9].

Existing endorsed clinical quality measures report on the percentage of patients who received initial screening for colorectal cancer [10, 11]. This eCQM can be used to measure rates of timely completion of the full screening process after positive non-invasive colorectal cancer screening stool-based test results to help improve health care delivery and quality in medical facilities and health systems across the U.S.

  1. Key Statistics for Colorectal Cancer. American Cancer Society. Accessed October 31, 2024. https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html.
  2. Corley DA, Jensen CD, Quinn VP, et al. Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. JAMA. 2017;317(16):1631-1641. doi:10.1001/jama.2017.3634. PMID: 28444278.
  3. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. doi:10.1038/ajg.2017.174. PMID: 28555630.
  4. Lopes G, Stern MC, Temin S, et al. Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline [published correction appears in JCO Oncol Pract. 2022 Nov;18(11):775-778. doi: 10.1200/OP.22.00580]. J Glob Oncol. 2019;5:1-22. doi:10.1200/JGO.18.00213. PMID: 30802159.
  5. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement [published correction appears in JAMA. 2021 Aug 24;326(8):773. doi: 10.1001/jama.2021.12404]. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238. PMID: 34003218.
  6. Burke CA, Lieberman D, Feuerstein JD. AGA Clinical Practice Update on Approach to the Use of Noninvasive Colorectal Cancer Screening Options: Commentary. Gastroenterology. 2022;162(3):952-956. doi:10.1053/j.gastro.2021.09.075. PMID: 35094786.
  7. Mutneja HR, Bhurwal A, Arora S, Vohra I, Attar BM. A delay in colonoscopy after positive fecal tests leads to higher incidence of colorectal cancer: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36(6):1479-1486. doi:10.1111/jgh.15381. PMID: 33351959.
  8. Mohl JT, Ciemins EL, Miller-Wilson LA, Gillen A, Luo R, Colangelo F. Rates of Follow-up Colonoscopy After a Positive Stool-Based Screening Test Result for Colorectal Cancer Among Health Care Organizations in the US, 2017-2020. JAMA Netw Open. 2023;6(1):e2251384. Published 2023 Jan 3. doi:10.1001/jamanetworkopen.2022.51384. PMID: 36652246.
  9. Ciemins EL, Mohl JT, Moreno CA, Colangelo F, Smith RA, Barton M. Development of a Follow-Up Measure to Ensure Complete Screening for Colorectal Cancer. JAMA Netw Open. 2024;7(3):e242693. Published 2024 Mar 4. doi:10.1001/jamanetworkopen.2024.2693. PMID: 38526494.
  10. #0034 Colorectal Cancer Screening (COL). NQF: Quality Positioning System. Updated March 26. 2023. Accessed May 24, 2024. https://www.qualityforum.org/Qps/QpsTool.aspx#qpsPageState=%7B%22TabType%22%3A1.
  11. Quality ID #113 (NQF 0034). Centers for Medicare & Medicaid Services. Accessed October 31, 2024. https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2023_Measure_113_MIPSCQM.pdf. 
1.20 Types of Data Sources
1.25 Data Source Details

Health System 1 data were used to calculate the eCQM rates, assess feasibility, and conduct reliability and validity testing. All analyses were conducted using data routinely collected and documented in the Epic EHR and reported for six years (2018 to 2023). Six facility groups were included in the analyses.

Health System 2 data were used to calculate eCQM rates and assess feasibility. All analyses were conducted using data routinely collected and documented in the Cerner (now Oracle Health) EHR and reported for eight years (2016 to 2023). One facility group was included in the analyses.

Health System 3 data were used to assess feasibility using the Allscripts EHR. eCQM rates are forthcoming.